IMPACT OF EMPAGLIFLOZIN ON ENDOTHELIAL FUNCTION IN NON-DIABETIC CHRONIC KIDNEY DISEASE

Abstract

The article presents findings from a study investigating the effects of empagliflozin on endothelium-dependent vasodilation (EDVD) in patients with chronic kidney disease (CKD) stages 1-3 who do not have diabetes mellitus (DM). The study included 120 patients with stage 1-3 CKD, with a biopsy confirmed diagnosis of glomerulonephritis. Patients were divided into three groups according to the CKD stage, and each group was further divided into two subgroups: subgroup A received empagliflozin at a dose of 10 mg, while subgroup B received only standard primary treatment. EDVD was measured using the reactive hyperemia test before treatment and after 3 months.
The results demonstrated a significant improvement in EDVD levels in patients receiving empagliflozin. Specifically, in subgroup 3A, the percentage of patients with normalized EDVD increased from 17.4% to 56.25% after treatment (p < 0.0001). In subgroup 2A, this indicator increased from 45.5% to 91.9% (p < 0.0001). In contrast, no significant changes in EDVD levels were observed in patients who did not receive empagliflozin (p > 0.05).
Thus, it was established that empagliflozin improves endothelial function and enhances vascular dilation capacity in patients with CKD without DM. These findings suggest that the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors may also be beneficial for patients with CKD.